

1 Dalmore Drive,
Scoresby,
Victoria 3179
AUSTRALIA
T: +61 (0)3 9763-1287
F: +61 (0)3 9763-2817
www.generabiosystems.com

Monday 25 March 2019

**ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX: GBI)
ENTITLEMENT OFFER SHORTFALL NOTICE**

Genera Biosystems Limited (**Company**) announces advises that the \$11,365,031 four for five non-renounceable entitlements issue (Entitlements Issue) as announced on 31 January 2019 closed on 20 March 2019.

Applications were received under the Entitlements Issue for a total of 1,869,712 fully paid ordinary shares for a total subscription amount received of \$243,062. This comprises 1,753,211 entitlement shares and 116,501 additionally subscribed shares.

Pursuant to the ASX Listing Rules, the Company gives notice of a shortfall in subscriptions of 86,179,833 shares (Shortfall Shares). Under the terms of the Rights Issue, the Company has the right to place any or all of the remaining Shortfall Shares within three months after the Closing Date (i.e. by 19 June 2019) on the same terms as the Rights Issue.

As the Minimum Subscription under the Entitlements Issue was not met the Company's share register Computershare shall hold the Application Amounts on trust subject to the Minimum Subscription level being met via the placement of Shortfall Shares.

Should the Minimum Subscription level be met via the placement of Shortfall Shares by no later than 30 April 2019 the Company will issue and allot all New Shares by 7 May 2019.

Should the Minimum Subscription not be received by 30 April 2019, the Company will repay all Application Amounts in full without interest as soon as practicable or issue a supplementary or replacement Prospectus and allow Applicants one month in which to withdraw their Applications and be repaid their Applicant Amount in full without interest.

The Shares of the Company shall remain suspended from trade on ASX until further notice.

For further information please contact:

Mr Richard Hannebery
Chief Executive Officer
Genera Biosystems Limited
Telephone: +61 (0)3 9763 1287
www.generabiosystems.com.au

About Genera Biosystems : Genera Biosystems Limited (“GBI”) is an Australian Securities Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests.

Genera’s single-well high multiplex AmpaSand® testing platform can detect up to 125 target analytes in a single-well of a reaction plate. Unlike traditional real-time PCR approaches, AmpaSand® single-well multiplex tests when run on a seamlessly integrated flow cytometry and liquid handling system can provide unparalleled throughput capability and cost efficiency for high volume pathology laboratories qualitative molecular testing needs.¹

Genera manufactures products in its Australian Therapeutics Goods Administration certified manufacturing facility in Scoresby, Victoria, Australia.

PapType®, an ARTG listed and CE-marked MDx test, simultaneously detects and identifies 14 high-risk types of HPV and 2 low risk HPV types in a single-well. These high-risk HPV types are responsible for 99.7% of all cases of cervical cancer.

In addition to PapType®, Genera has also commercialized and gained ARTG listing and CE mark for RTIplex™, a single-well multiplex MDx that identifies 15 common upper respiratory tract pathogens, including Influenza A & B, as well as 10 other viral and 3 bacterial disease-causing microbial targets.

Genera’s development pipeline includes a new 8-plex sexually transmitted infections panel that is expected to be available in 2019, with plans to broaden the AmpaSand® test menu further to 6 highly competitive single-well multiplex MDx assays by 2020.

PapType®, RTIplex™, and the tests in development, employ the AmpaSand® biochemistry as well as Genera’s proprietary ARTG listed and CE-IVD marked QPlots automated analytical and reporting software that is compatible with most Laboratory Information Management Systems (‘LIMS’) . All the components of the Genera MDx system, including AmpaSand® and QPlots, have been optimized to run on Beckman Coulter’s innovative CytoFLEX™ flow cytometry system.

¹ All ‘plate based’ Real Time PCR platforms can ‘multiplex’ up to 4 targets per well assuming 4 available channels of a Real Time PCR instrument. To multiplex greater than 4 target analytes in a test most platforms require use of additional wells of a plate to test for the additional target analytes. As such commercially, their multiplexing capability is restricted due to a direct trade-off with volume throughput per plate (96 or 384 well). Genera’s AmpaSand® technology facilitates the multiplexing of up to ~125 target analytes **in a single-well** of a plate. On a like for like basis depending on the number of target analytes detected in a multiplex assay Genera’s AmpaSand® technology facilitates > 4X relative volume throughput. High volume throughput is a key commercial consideration for all large pathology labs undertaking HPV and STI testing.